Treatment · 9 min read · Updated April 2026

Itraconazole for Lung Cancer: Clinical Trial Data and Hedgehog Inhibition

Itraconazole has Phase II combination trial data in non-small cell lung cancer showing survival benefit. It inhibits the Hedgehog pathway and angiogenesis via VEGFR2. Generic, $15-30/month.

🔬 Grade B: Promising

The Bottom Line

Itraconazole has the strongest clinical evidence among repurposed drugs for non-small cell lung cancer (NSCLC). A Phase II combination trial showed survival advantage when itraconazole was added to standard chemotherapy in relapsed NSCLC. Xenograft studies showed 72-79% tumor growth reduction. The mechanism hits two validated cancer targets: Hedgehog signaling and VEGFR2-mediated angiogenesis. Both are established drug targets in lung cancer, making itraconazole's dual activity particularly compelling.

Clinical Evidence

  • A Phase II combination chemotherapy trial in relapsed NSCLC showed survival advantage when itraconazole was added (PMC5529765). This is human clinical data, not just cell lines.
  • NSCLC xenograft models showed 72-79% tumor growth reduction (p<0.001) in two separate models (PMC5588108). Two independent models showing the same result is a strong preclinical signal.
  • The ReDO Project reviewed itraconazole for cancer repurposing on ecancer.org, citing prostate cancer, lung cancer, and basal cell carcinoma as the three indications with the strongest clinical signals.
  • The same drug showed 48% PSA progression-free survival at 24 weeks in the Johns Hopkins prostate cancer Phase II trial (PMC3579600), establishing the clinical dosing range used in subsequent trials.

The Mechanism

Itraconazole has two separate anticancer pathways, both of which are validated targets in lung cancer:

1. Hedgehog pathway inhibition

The Hedgehog signaling pathway is aberrantly activated in many NSCLCs and drives the survival of tumor stem cells, the cells responsible for treatment resistance and relapse. Itraconazole blocks Smoothened (SMO), a protein required for Hedgehog pathway activation. This is the same target as two FDA-approved Hedgehog inhibitors, vismodegib and sonidegib, but itraconazole binds to a different site on SMO. This distinction matters: it means itraconazole may retain activity in tumors that have developed resistance to standard Hedgehog inhibitors.

2. VEGFR2 inhibition (anti-angiogenesis)

Tumors cannot grow beyond a few millimeters without recruiting new blood vessels. VEGFR2 is the primary receptor driving this process, and blocking it starves tumors of the blood supply they need to expand. This is the same target as bevacizumab (Avastin), a standard treatment for advanced NSCLC. Itraconazole inhibits VEGFR2 through a different mechanism than bevacizumab, which means the two approaches are not redundant and may be combinable. Bevacizumab costs tens of thousands of dollars per year. Generic itraconazole costs $15-30/month.

Itraconazole vs Standard Hedgehog Inhibitors

Vismodegib (Erivedge) and sonidegib (Odomzo) are FDA-approved SMO inhibitors used in basal cell carcinoma and being studied in other Hedgehog-driven cancers. Both cost over $10,000 per month, and both have a well-documented problem: resistance develops quickly, often within months, as tumors acquire mutations in SMO that block drug binding.

Itraconazole binds to a different site on SMO than either drug. This is not a minor pharmacological detail: it means that SMO mutations that confer resistance to vismodegib or sonidegib do not necessarily confer resistance to itraconazole. Whether itraconazole retains clinical activity in patients who have progressed on standard Hedgehog inhibitors is an active area of investigation. The mechanistic case is sound.

Practical Information

  • Dose: 600mg/day was the active dose in cancer trials. The 200mg/day arm in the Johns Hopkins prostate trial showed no significant antitumor effect, which is important: standard antifungal dosing (200mg) appears insufficient for anticancer activity.
  • Administration: Take with food. Itraconazole absorption requires gastric acid. Avoid proton pump inhibitors (PPIs) if possible, as they reduce absorption.
  • Cost: Generic, approximately $15-30/month.
  • Drug interactions (critical): Itraconazole is a potent inhibitor of CYP3A4, the liver enzyme responsible for metabolizing many chemotherapy drugs including docetaxel, paclitaxel, vincristine, and others. Combining itraconazole with these drugs can significantly raise chemotherapy blood levels. A prescribing physician must review the full medication list before combining itraconazole with any chemotherapy.
  • Monitoring: Liver enzymes (ALT, AST) should be monitored. Azole antifungals carry hepatotoxicity risk, particularly at the higher doses used in cancer protocols.
  • Prescription: Any physician can prescribe itraconazole off-label. It is FDA-approved as an antifungal.

Related Research

Sources

Medical Disclaimer: This is a research review, not medical advice. Always consult with qualified healthcare professionals before making any changes to your health regimen.

How we grade evidence: Grade A = Phase II+ RCT with positive signal. Grade B = Phase I/II or strong epidemiology. Grade C = Preclinical only. Debunked = Retracted or disproven. Full methodology →